RE:RE:RE:RE:The RPSGood point GV. I must admit I haven't paid too much attention in terms of thinking about the restructured royalties but having read all the posts here and on Agora I'm feeling really good right now.
It provides reduced cost to RVX in terms of exploring compounds and hence it provides increased flexibility.
On the Zenith side it opens doors for possibilities I have not thought through (e.g. in terms of Zenith Capital).
Ever since the ASSURE trial ended, from my perspective, there has been nothing but positive and remarkable scientific findings. And now with the kidney data we have another positive sign that things can move ahead. The phrase on my mind right now is there is "no evidence of toxicity in any data"(hope I am not wrong on this). Years ago when I was 26 years old I had embryonal and chorio carcinoma of my left testicle (I was told I'd be dead in 6 months) and I had surgery and the 4 months of bleomycin and vinblastin chemo. I'm not sure what toxicity is scientifically but those drugs put me on my back for about 10 days after each treatment over 4 months. The good news is that I lost 40 pounds because I couldn't eat. AND "I think" I'm still alive...hahaha!
From everything I'v read about apebetalone it seems to be anything but toxic. In fact, I'm not a scientist, but it seems to be the opposite of toxic.
So back to Sarah's explanation, when she talks about the post hoc discoveries and the implications for royalty restructuring it seem s to make sense.
Of course we are being told only a very small part of the story for obvious reasons. They probably know so much about the 2400 Zenith compounds and 1500 RVX compounds from in vitro testing and given the sophistication of the analytical tools they are using now they have probably been able to evolve their compound X indiaction segmentation significantly since when Zenith was formed in Early June 2013. Both of these companies seem to have attracted very talented scientists.
So now when it comes to the revenue side it seems to me that revenues for apabetalone and zen3694 are very distant in the future e.g. perhaps 2021 earliest. However, successful trials could very well attract suitors much sooner as trial results (futility analysis and the mCRPC results 2017) and the science evolves.
There are some obvious potentials as in Pfizer (enzalutimde) with zen3694 and AZ with Crestor and apabetalonne.
Or there could be Don's continuing chess game which I personally feel could be setting up the possibility of downstream production, marketing and sales. For example Hepalink and apabetalone.
The next licensing deal will be very telling in terms of Don's chess game.
There are also other revenue streams such as licensing various compounds to other biotechs for research purposes. Plus there is also the blood bank that Don has mentioned many times and I don't understand.
It is a funny thing but when I read about other compounds in trials they strike me as just chemicals. But when I read about apabetalone, for example, the impacts seem profound e.g.
RVX-208 modulates gene transcription and has effects on pathways known to play important roles in CVD risks including the complement, coagulation, inflammation, and metabolism as well as increasing levels of the apolipoprotein A-I (apoAI), the major protein in high density lipoprotein(HDL).
Hence, I guess, looking at Alzheimers, chronic kidney disease and various other inflammatory conditions.
Just rambling here. It was a good week and I am very excited!
Finally, I am speculating that with this restucturing, it is only the first move. I think something is up and Don is both trying to create value and protect.
Just my opinion and pure speculation.
GLTA
Toinv